Xilio Therapeutics, Inc. XLO
9.04
0.04
0.44%
as of 25 Sep
- Market cap
- $59.2M
- P/E
- 0.0×
Follow XLO
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (55.03%) | (75.20%) | (132.53%) | (908.28%) |
+8 more TTM periods Free account |
|
| (15.16%) | (23.43%) | (31.04%) | (56.14%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(19.04%) | (27.23%) | (37.82%) | (81.96%) | |
Average Days of Receivables |
34.17 | 0.00 | 41.70 | 200.84 | |
Free Cash Flow per Share |
(3.16) | (3.51) | (0.66) | (1.71) | |
Free Cash Flow |
(61.27) | (57.36) | (5.51) | (17.58) | |
Capital Expenditures |
(0.67) | (1.05) | (0.52) | (0.43) | |
Piotroski F-Score |
3.00 | 3.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(29.09%) | (25.27%) | (2.89%) | (17.93%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
104.28% | 126.40% | 128.04% | 147.00% | |
Selling, General and Administrative Expense of Revenue |
44.66% | 52.58% | 67.88% | 90.64% | |
Share Based Compensation of Revenue |
12.27% | 14.24% | 15.85% | 17.37% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.78 | 1.80 | 0.14 | 0.29 | |
Depreciation/Fixed assets |
0.40 | 0.38 | 0.40 | 0.43 | |
Capex/Depreciation |
(0.50) | (0.76) | (0.34) | (0.27) | |
Revenue per Share |
3.30 | 3.27 | 5.24 | 3.09 | |
Operating CF per Share |
(3.12) | (3.44) | (0.60) | (1.67) | |
Capex per Share |
(0.03) | (0.06) | (0.06) | (0.04) | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.01 | |
Net Profit Margin |
(34.06%) | (58.52%) | (80.05%) | (183.90%) |
Columns are period end dates